Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus FLAG-GO vs FLAG-GO in relapsed pediatric AML
2023-510160-12-00Phase 3Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Overall survival. Planned start Jul 2024; status: authorised.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510160-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510160-12-00.